Replies to post #110773 on Biotech Values

[rkrw]

On Deciphera I don't know much.

[mcbio]

Re: Deciphera/ARIA

Any sense on this agent from Deciphera? I see that Dr. Moshe Talpaz is one of the principal Investigators.

clinicaltrials.gov/ct2/show/NCT00827138

As this is just a Phase 1 due for primary completion in June 2011, Deciphera is clearly behind ARIA and ponatinib, not that they couldn't represent competition in the future though. Also, note under "Intervention Details" where it indicates "transitioning from once a day to twice a day dosing based on safety and PK data." Ponatinib is QD and not sure what is meant by the reference to safety data. Was Deciphera seeing safety issues at a high QD dose and therefore having to transition to a lower BID dose to address safety/PK?